Michael Frederick Press, MD, PhD

Professor of Pathology

Harold E. Lee Chair in Breast Cancer Research

Director of Breast Cancer Analysis Lab

Image of Michael Frederick Press, MD, PhD
Is this your profile? Click to edit

Overview

Michael F. Press, M.D., Ph.D. is a professor in the Department of Pathology and co-leader of the Women’s Cancers Program. He received his M.D., Ph.D. and residency training at the University of Chicago. He was a member of the University of Chicago faculty for seven years before joining the faculty of the University of Southern California in 1988. Dr. Press is currently the director for the Breast Cancer International Research Group Central Laboratory, the coordinator of the Breast Cancer Program at USC Norris Cancer Center and holds the Harold E. Lee Chair in Cancer Research in the USC Norris Cancer Center. His research interests are molecular genetic alterations in breast and gynecologic cancers.

Research Funding

  • HER-2 NEU PROTO-ONCOGENE IN OVARIAN &ENDOMETRIAL CANCER
    NIH · R01CA050589 · Feb 1, 1991 – Jan 31, 1995 · Role: Principal Investigator
  • PATHOBIOLOGY OF BREAST CANCER AND HORMONE RECEPTORS
    NIH · R01CA048780 · Apr 1, 1988 – Jan 31, 2006 · Role: Principal Investigator

Publications

  • Integrating multi-ancestry genomic and proteomic data to identify blood risk biomarkers and target proteins for breast cancer genetic risk loci. Int J Cancer. 2025 11 15; 157(10):2071-2080.. View in PubMed
  • Analytical Comparison of Commonly Used Laboratory-Developed Tests for the Assessment of Ki-67 in Breast Carcinoma With a Food and Drug Administration-Approved Benchmark. Mod Pathol. 2025 10; 38(10):100813.. View in PubMed
  • Early Detection of Ovarian Cancer Using Cell-Free DNA Fragmentomes and Protein Biomarkers. Cancer Discov. 2025 Jan 13; 15(1):105-118.. View in PubMed
  • Refining breast cancer genetic risk and biology through multi-ancestry fine-mapping analyses of 192 risk regions. Nat Genet. 2025 01; 57(1):80-87.. View in PubMed
  • Impact of CCND1 amplification on the prognosis of hormone receptor-positive, HER2-negative breast cancer patients-correlation of clinical and pathological markers. Breast Cancer Res Treat. 2025 Feb; 210(1):125-134.. View in PubMed
  • Case-Case Genome-Wide Analyses Identify Subtype-Informative Variants That Confer Risk for Breast Cancer. Cancer Res. 2024 08 01; 84(15):2533-2548.. View in PubMed
  • Correlation of RANK and RANKL with mammographic density in primary breast cancer patients. Arch Gynecol Obstet. 2024 08; 310(2):1223-1233.. View in PubMed
  • Genome-wide association analyses of breast cancer in women of African ancestry identify new susceptibility loci and improve risk prediction. Nat Genet. 2024 May; 56(5):819-826.. View in PubMed
  • Using genome and transcriptome data from African-ancestry female participants to identify putative breast cancer susceptibility genes. Nat Commun. 2024 May 02; 15(1):3718.. View in PubMed
  • Novel breast cancer susceptibility loci under linkage peaks identified in African ancestry consortia. Hum Mol Genet. 2024 04 08; 33(8):687-697.. View in PubMed